Michael Miller.

The selecting of a medical benefit in cardiovascular result with niacin, although based on a small number of events, provides additional support for the validity of this imaging end stage and is consistent with outcome effects observed in other trials.6-8 Further clinical certainty regarding ezetimibe and niacin will require data from ongoing clinical trials. The use of ezetimibe led to a paradoxical upsurge in the amount of atherosclerosis in association with greater reduction in LDL cholesterol, an impact we hypothesize may stem from unintended biologic effects of this agent..Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA qualified to receive approval by the U.S. Food and Medication Administration . Upon acceptance, BENLYSTA would be the first-ever treatment developed for lupus specifically, and the first new FDA-approved drug for lupus in a lot more than 50 years. 2. Ad Council Launches its First-Ever National Public Consciousness Campaign on Lupus The Advertisement Council launched its initial national multi-media public consciousness advertising campaign for lupus.